Jove
Visualize
Contáctanos
JoVE
x logofacebook logolinkedin logoyoutube logo
ACERCA DE JoVE
Visión GeneralLiderazgoBlogCentro de Ayuda JoVE
AUTORES
Proceso de PublicaciónConsejo EditorialAlcance y PolíticasRevisión por ParesPreguntas FrecuentesEnviar
BIBLIOTECARIOS
TestimoniosSuscripcionesAccesoRecursosConsejo Asesor de BibliotecasPreguntas Frecuentes
INVESTIGACIÓN
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchivo
EDUCACIÓN
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualCentro de Recursos para ProfesoresSitio de Profesores
Términos y Condiciones de Uso
Política de Privacidad
Políticas

Videos de Conceptos Relacionados

Direct-Acting Cholinergic Agonists: Pharmacokinetics01:31

Direct-Acting Cholinergic Agonists: Pharmacokinetics

1.9K
Direct-acting cholinergic agonists, such as synthetic choline esters and naturally occurring alkaloids, exert their effects by enhancing the actions of acetylcholine and stimulating the parasympathetic nervous system. Synthetic choline esters share structural similarities with acetylcholine. For example, they have a positively charged quaternary ammonium or onium group, contributing to their hydrophilic characteristics. As a result, they are poorly absorbed in the body through oral...
1.9K
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

990
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
990
Direct-Acting Cholinergic Agonists: Therapeutic Uses01:11

Direct-Acting Cholinergic Agonists: Therapeutic Uses

1.8K
Direct-acting cholinergic agonists have many therapeutic uses in various medical fields. Choline esters, including acetylcholine, have limited clinical utility due to their non-selectivity and short duration of action. Still, acetylcholine and carbachol are applied topically during ophthalmologic surgery to induce miosis. Pilocarpine, a muscarinic and ganglionic stimulator, effectively treats open-angle glaucoma and alleviates xerostomia and dry mouth caused by radiotherapy or Sjögren...
1.8K
Indirect-Acting Cholinergic Agonists: Pharmacokinetics01:22

Indirect-Acting Cholinergic Agonists: Pharmacokinetics

1.6K
Indirect-acting cholinergic agonists, or anticholinesterases, enhance the body's cholinergic activity by inhibiting acetylcholine's breakdown. They are categorized as reversible or irreversible agents based on their mechanism of action. They are further classified into short-acting, intermediate-acting, and long-acting agents based on their duration of action.
Reversible agents containing quaternary amines, such as neostigmine and edrophonium, are not easily absorbed orally because they...
1.6K
Adrenergic Agonists: Direct-Acting Agents01:30

Adrenergic Agonists: Direct-Acting Agents

2.8K
Drugs that mimic the action of endogenous catecholamines like noradrenaline and adrenaline are called adrenergic agonists or sympathomimetics. Based on their mechanism of action, sympathomimetics can be classified as direct-, indirect-, or mixed-acting sympathomimetics. Direct-acting adrenergic agonists activate adrenoceptors without affecting presynaptic neurons, making them independent of neuronal catecholamine-depleting agents like reserpine and guanethidine.
These agents can be classified...
2.8K
Adrenergic Agonists: Indirect-Acting Agents01:25

Adrenergic Agonists: Indirect-Acting Agents

2.8K
Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
2.8K

También podría leer

Artículos Relacionados

Artículos vinculados a este trabajo por autores compartidos, revista y gráfico de citas.

Ordenar por
Same author

Gender-Specific Associations Between Tobacco and Tobacco-Free Nicotine Use and Symptoms of Anxiety and Depression in Swedish Adolescents.

Tobacco use insights·2026
Same author

The glucagon-like peptide-1 receptor agonist, Ex4, reduces intromission in sexually experienced male mice.

Psychoneuroendocrinology·2026
Same author

Behavioral dynamics of different stages of sexual motivation in male and female rats.

Journal of neuroscience methods·2026
Same author

The Acetylcholine Esterase Inhibitor Donepezil Increases Dopamine Levels in the Nucleus Accumbens and Blocks the Alcohol Deprivation Effect in Rats.

Addiction biology·2026
Same author

Tirzepatide attenuates mesolimbic cocaine-evoked dopamine levels and reduces cocaine taking, motivation and seeking behaviours in male rodents.

EBioMedicine·2026
Same author

Sleep deprivation in zebrafish larvae: Behavior and cognitive alterations.

Progress in neuro-psychopharmacology & biological psychiatry·2026

Video Experimental Relacionado

Updated: Feb 9, 2026

Assessment of Sexual Behavior of Male Mice
04:38

Assessment of Sexual Behavior of Male Mice

Published on: March 5, 2020

21.9K

Agonistas de los receptores GLP-1 de acción corta y prolongada disminuyen los comportamientos sexuales femeninos en

Olesya Shevchouk1, Christian E Edvardsson1, Mia Ericson2

  • 1Institute of Neuroscience and Physiology, Department of Pharmacology, The Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden.

Behavioural brain research
|February 7, 2026
PubMed
Resumen

Los agonistas del receptor del péptido similar al glucagón tipo 1 (GLP-1R) impactan los comportamientos sexuales y sociales femeninos, con efectos que varían según el fármaco y la especie. Estos hallazgos revelan impactos específicos de la especie y del agonista en las funciones de recompensa femeninas.

Palabras clave:
ADICCIÓNDopaminapéptidos reguladores del apetitopéptidos intestino-cerebro

Más Videos Relacionados

Phenotypic Analysis of Rodent Malaria Parasite Asexual and Sexual Blood Stages and Mosquito Stages
08:23

Phenotypic Analysis of Rodent Malaria Parasite Asexual and Sexual Blood Stages and Mosquito Stages

Published on: May 30, 2019

12.2K
A System for Tracking the Dynamics of Social Preference Behavior in Small Rodents
08:38

A System for Tracking the Dynamics of Social Preference Behavior in Small Rodents

Published on: November 21, 2019

8.2K

Videos de Experimentos Relacionados

Last Updated: Feb 9, 2026

Assessment of Sexual Behavior of Male Mice
04:38

Assessment of Sexual Behavior of Male Mice

Published on: March 5, 2020

21.9K
Phenotypic Analysis of Rodent Malaria Parasite Asexual and Sexual Blood Stages and Mosquito Stages
08:23

Phenotypic Analysis of Rodent Malaria Parasite Asexual and Sexual Blood Stages and Mosquito Stages

Published on: May 30, 2019

12.2K
A System for Tracking the Dynamics of Social Preference Behavior in Small Rodents
08:38

A System for Tracking the Dynamics of Social Preference Behavior in Small Rodents

Published on: November 21, 2019

8.2K

Área de la Ciencia:

  • Neurociencia; Endocrinología; Ciencia Conductual

Sus antecedentes:

  • Los agonistas del receptor del péptido similar al glucagón tipo 1 (GLP-1R) influyen en las vías metabólicas y de recompensa.; Estudios previos muestran que los agonistas del GLP-1R de acción corta afectan el comportamiento sexual masculino, pero se desconocen las respuestas femeninas.

Objetivo del estudio:

  • Investigar los efectos de los agonistas del GLP-1R de acción prolongada (dulaglutida, liraglutida) y de acción corta (exendina-4) sobre los comportamientos sexuales y sociales en ratas y ratones hembras.; Explorar los posibles mecanismos neuroquímicos subyacentes a estos cambios conductuales.

Principales métodos:

  • Administración de agonistas del GLP-1R (dulaglutida, liraglutida, exendina-4) a ratas y ratones hembras sexualmente experimentados.; Evaluación de comportamientos sexuales (p. ej., montas, intromisiones, lordosis) y comportamientos sociales (p. ej., novedad social, sociabilidad) utilizando paradigmas conductuales establecidos.; Análisis de cambios neuroquímicos en el núcleo del tracto solitario (NTS) y el septo lateral (LS).

Principales resultados:

  • Los agonistas del GLP-1R disminuyeron los comportamientos sexuales en ratas y ratones hembras, con notables diferencias específicas del fármaco y de la especie.; La liraglutida y la dulaglutida redujeron la novedad social y aumentaron la sociabilidad en ratones hembras.; Las alteraciones neuroquímicas incluyeron un aumento de la noradrenalina en el NTS y cambios en el glutamato, la glutamina y la taurina en el LS.

Conclusiones:

  • La activación del GLP-1R ejerce efectos específicos de la especie y del agonista sobre los comportamientos sexuales y sociales femeninos.; Estos hallazgos amplían la comprensión del papel del GLP-1 en la modulación de los comportamientos relacionados con la recompensa más allá de las funciones metabólicas.